tbuckley/cabot-search huggingface dataset:
LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
Authors: S. Kasper-Virchow, R.D. Hofheinz, S. Stintzing, T.N. Dechow, T.J. Ettrich, M. Sinn, C. Roderburg, L. Fischer von Weikersthal, U. Graeven, C. Mueller, J. Meiler, A. Stein, D.P. Modest, C. Pauligk, I. Virchow, J.T. Siveke, S-E. Al-Batran, M.H.H. Schuler, T.O. Goetze
Journal: Annals of Oncology (2024)
LBA18 Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
Authors: N. Lin, E.M. Ciruelos, G. Jerusalem, V. Mueller, N. Niikura, G. Viale, R. Bartsch, C. Kurzeder, R. Connolly, S.E. Baron-Hay, M. Gion Cortes, V. Guarneri, G. Bianchini, H. Wildiers, S. Escrivá-de-Romaní, M. Prahladan, H. Bridge, S. Verma, N. Harbeck
Journal: Annals of Oncology (2024)
227TiP A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H)
Authors: G.A. De Velasco Oria, E. Garralda, R. Bernabe Caro, I. Braña, S. Pons, E. Garrido, R. Galan Servan, L.G. Paz-Ares
Journal: Annals of Oncology (2024)
LBA32 A randomized, phase II, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: Safety, efficacy and dose optimization (PRESERVE-004/GOG-3081)
Authors: J.N. Barlin, P.C. Lim, J. Thomes Pepin, E.E. Hopp, N.G. Cloven, C. Lee, H.D. Eshed, D. Black, H.M. Cottrill, L. Hand, D.M. O'Malley, L.T. Chuang, L. Willmott, M. Chisamore, S. Shpyro, J. Durbin, P. Zheng, Y. Liu, B.J. Monk
Journal: Annals of Oncology (2024)
1662TiP HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Authors: Q. Qin, S. Zhang, C.C. Jiang, K. Courtney, J. Wang, W. Arafat, S. Cole, E. Heath, R. Ploski, T. Zhang
Journal: Annals of Oncology (2024)
192P Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers
Authors: D. Palmer, S. Kapoor, S. Khandelwal, Y. Ullal, Y. Narvekar, A. Ghosh, A. Dey, A. Kumar, R. Ps, A. Tyagi, A. Agrawal, M.P. Castro, J. Wingrove, B. Greenhalf
Journal: Annals of Oncology (2024)
230TiP Exploring mechanisms of action and resistance in innovate cancer therapies: The UNLOCK program
Authors: B. Alonso de Castro, J.E. Rodriguez, M.F. Mosele, C. Nicotra, M. Ngo Camus, J. Scoazec, D. Vasseur, L. Bigot, S. Nikolaev, J. Wang, J-C. Gerome, F. Brayé, F. André, S. Ponce Aix, C.P. Massard, A. Italiano, Y. Loriot, L. Friboulet
Journal: Annals of Oncology (2024)
LBA60 Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
Authors: Z. Peng, J. Wang, Y. Zhang, H. Li, Q. Zhao, X. Zhu, S. Wei, Y. Cheng, W. Yang, J. Yao, M. Zhang, L. Xie, X. Zhang, P. Zhao, C. Hu, J. Zhang, Z. Wang, W. Wang, H. Han, L. Shen
Journal: Annals of Oncology (2024)
199P Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival
Authors: Q. Xie, J. Liang, R. Li, G. Xu, R. Lei, Z. Lin, Y. Xu, T. Sun, B. Zhang, Y. Peng
Journal: Annals of Oncology (2024)
LBA61 Conventional oral morphine vs. IV patient-controlled analgesia (IPCA) with either hydromorphone (HM) continuous infusion plus rescue dose (CIRD) or HM bolus-only (BO) for severe cancer pain: A randomized phase III study
Authors: R. Lin, L. He, M. Lu, Q. Wan, Y. Chen, J. Liu, X. Lu, L. Zhuang, Z. Zhang, L. Gong, Y. Luo, T. Ren, L. Cao, J. Liu, H. Zou, L. Cui, C. Shang, S. Chen, S. Lin, C. Huang
Journal: Annals of Oncology (2024)
LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
Authors: B.I. Rini, C. Suarez Rodriguez, L. Albiges, K. Jalkanen, G.A. De Velasco Oria, M. Burotto, P. Ghatalia, R. Iacovelli, E.T. Lam, E. Verzoni, M. Gumus, W. Stadler, C.K. Kollmannsberger, B. Melichar, B. Venugopal, J. Lin, R. Perini, D. Vickery, T.K. Choueiri, T.B. Powles
Journal: Annals of Oncology (2024)
LBA47 Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
Authors: A.M. Di Giacomo, E. Simonetti, L. Calabro, V. Vegni, F. Santangelo, R. Depenni, M. Colucci, M. Valente, R. Grifoni, M.F. Lofiego, G. Amato, H.N. Keer, A. Oganesian, D. Chan, D. Giannarelli, M. Altomonte, M. Ceccarelli, A. Anichini, A. Covre, M. Maio
Journal: Annals of Oncology (2024)
LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Authors: M.S. Trivedi, R.A. Shatsky, R. Nanda, H.S. Rugo, C. Omene, K. Kalinsky, E.T. Roussos Torres, B. Thomas, A. Sanford, K.S. Albain, A.S. Clark, C.I. Falkson, C. Isaacs, A. Thomas, J. Tseng, L.J. Van't Veer, N. Hylton, D. Yee, C. Yau, L. Esserman
Journal: Annals of Oncology (2024)
LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial
Authors: F. Saad, E. Vjaters, N.D. Shore, D. Olmos, N. Xing, A.J.P.D.S. Gomes, A.C.A. Mota, P. Salman, M. Jievaltas, A. Ulys, M. Jakubovskis, E. Kopyltsov, W. Han, L. Nevalaita, I. Testa, M-A. Le Berre, I. Kuss, H. Kunhiparambath
Journal: Annals of Oncology (2024)
LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria
Authors: J. de la Haba Rodriguez, J. Cortés, S. Di Cosimo, I. Blancas López-Barajas, S.P. Cortez Castedo, A. López, E. López-Miranda, H. Pla Juher, C.R. Albacar Miro, J. Ponce, V. Carañana Ballerini, L. Paris Bouzas, M. Valero Arbizu, M.R.B. Ruiz Borrego, V. Iranzo, A. Garrido, D. Alcalá-López, L. Mina, J.J. Garcia Mosquera, A. Llombart Cussac
Journal: Annals of Oncology (2024)
LBA64 Outcomes of BRCA and in-house homologous recombination deficiency (HRD) testing in women with ovarian and breast cancer: A multicentre registry study
Authors: K.S. Shohdy, L. Kassem, B.E.M. Gabriel, S. Lasheen, H. ElGhazawy, E.M. Barsoum, T. Elnahas, H.A. Azim
Journal: Annals of Oncology (2024)
LBA52 Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS &gt;/=50%) non-small cell lung cancer (NSCLC)
Authors: D.R. Spigel, E.P. Korbenfeld, H. Hayashi, R. Corre, B.C. Cho, A. Psyrri, M. Cobo Dols, E. Parkhomenko, D. Baxter, N. Patel, F. Trinchese, I. Diaz-Padilla, M. Reck
Journal: Annals of Oncology (2024)
LBA34 ENGOT-ov48/EUDARIO: European trial on enhanced DNA repair inhibition in ovarian cancer
Authors: N. Concin, T. Van Gorp, D. Lorusso, I.L. Ray-Coquard, A. Laenen, C. Zamagni, P. Harter, J. Sehouli, F. Raspagliesi, A.G. Zeimet, J-P. Lotz, V. Salutari, O. Tredan, R. Zeillinger, M. Dobbelstein, U. Moll, D. Kramer, E. Obermayr, I. Braicu, I.B. Vergote
Journal: Annals of Oncology (2024)
LBA85 TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)
Authors: M.S. van der Heijden, G. Simone, M. Boegemann, E. Xylinas, M. Roumiguié, F. Guerrero-Ramos, A. Necchi, S. Daneshmand, C. Van Praet, P. Spiegelhalder, K. Decaestecker, H. Arentsen, D. Zainfeld, S. Hampras, C.J. Cutie, H. Sweiti, K. Stromberg, J. Martin, A. Shukla, J.M. Jacob
Journal: Annals of Oncology (2024)
LBA26 SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
Authors: K. Ng, F-S. Ou, T. Zemla, N. McCleary, A. Kalyan, M. Shusterman, N. Vijayvergia, C. Wu, S.A. Cohen, S. Pulsipher, A. Shergill, L. Schwartz, D. Zuckerman, E.M. O'Reilly, J. Meyerhardt
Journal: Annals of Oncology (2024)
211P GynePDX: A new platform of preclinical models for endometrial and ovarian cancers
Authors: M. Denizli, B. Villafranca Magdalena, I. de la Calle Fuentes, M. Rebull, C. Masferrer-Ferragutcasas, F. Serra, L. Salazar, A. Luzarraga Aznar, S. Cabrera, A. Gil-Moreno, E. Colas
Journal: Annals of Oncology (2024)
LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study
Authors: N. Agarwal, A.A. Azad, J.C. Galceran, N. Matsubara, S. Oudard, F. Saad, A.S. Merseburger, A. Soares, B.A. McGregor, B. Zurawski, M. Tsiatas, S. North, E. Bournakis, L. Antonuzzo, D.S. Williamson, L. Evilevitch, A. Simmons, R. Ferraldeschi, P. Nandoskar, S.K. Pal
Journal: Annals of Oncology (2024)
200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
Authors: T. Bochtler, A. Krämer, C. Pauli, G. Durán-Pacheco, C. Arslan, F. Bigot, N. Chalabi, N. Cook, A. Italiano, F. Losa, J. Menezes, N. Ma, M. Ozguroglu, R.A. Pazo Cid, J.S. Ross, K-K. Shiu, P. Arni, H. Moch, L. Mileshkin
Journal: Annals of Oncology (2024)
LBA16 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Authors: K. Khoury, J.L. Meisel, J. Chien, A. Wallace, M. Arora, M. Rozenblit, N. Williams, R. Nanda, V. Borges, E. Stringer-Reasor, J. Boughey, C. Nangia, C. Vaklavas, H.S. Rugo, L.J. Van't Veer, A. DeMichele, N. Hylton, D. Yee, C. Yau, L. Esserman
Journal: Annals of Oncology (2024)
LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Authors: B. Besse, S-H. Lee, S. Lu, D. Stroyakovskiy, O. Yazici, J.R. Rodriguez Cid, H. Hayashi, D. Nguyen, J.C-H. Yang, M. Gottfried, A.C. Gelatti, S. Owen, S-H.I. Ou, M. Ennis, S. Sethi, J.M. Bauml, J. Zhang, J.C. Curtin, B.C. Cho
Journal: Annals of Oncology (2024)
193P Translational, PK, PD, and immunophenotyping analyses of tuvusertib + niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301)
Authors: A.W. Tolcher, T.A. Yap, R. Plummer, D. Sommerhalder, J. Rodon, M. Lagonera, P. Bergmann, V. Sanchez Perez, N. Wohlfeil, D. Wang, J. Kaur Mukker, G. Sessa, A. Manginelli, J.S. de Bono
Journal: Annals of Oncology (2024)
LBA22 Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
Authors: X. Hu, G. Curigliano, K. Yonemori, A. Bardia, C.H.E. Barrios, J. Sohn, C. Levy, W. Jacot, J. Tsurutani, K. Mezei, A. Roborel de Climens, X. Wu, N. Begbie, Z. Mbanya, R.A. Dent
Journal: Annals of Oncology (2024)
LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN
Authors: M. Reck, D. Gale, Z. Zhu, D. Harpole, J. Taube, T. Mitsudomi, D. Van Luong, M.J. Hochmair, K-Y. Lee, Y. Horio, L. Urban, H. Akamatsu, B. Biswas, L. Antonuzzo, Z. Szalai, R. Stewart, Z. Lai, D. Hodgson, G. Doherty, J.V. Heymach
Journal: Annals of Oncology (2024)
213P Constructing a high-definition patient-digital twin (PDT) in treatment-naïve women with advanced cancer
Authors: L.D. Garma, D. Jimenez, D. Vicente Baz, R. Vera, B. Bermejo, S. Gonzalez, S. Pernas Simon, J.M. Sanchez Torres, B. Nasarra-Lopez, B. Fullana Grimalt, M. Rodriguez, S. de la Cruz, L. Paz, M. Sauras, M.A. Villalba, A. Artes-Rodriguez, R. Colomer Bosch, M. Quintela-Fandino
Journal: Annals of Oncology (2024)
LBA20 First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
Authors: M. Kok, R.A.B. Voorthuis, L. De Boo, A.G.J. van Rossum, I. Mandjes, S. Balduzzi, M. Chelushkin, E.H. Rosenberg, H.M. Horlings, C.E. Loo, J.B. Heijns, M. Agterhof, B. De Valk, A-M.V. Riel, A. Van Der Velden, M. Dercksen, A. Imholz, A.E. van Leeuwen-Stok, H.M. Oosterkamp, S. Linn
Journal: Annals of Oncology (2024)
LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
Authors: L. Bergmann, M. Ahrens, L. Albiges, M. Gross Goupil, E. Boleti, G. Gravis, A. Flechon, M-O.J. Grimm, S. Rausch, P. Barthelemy, D.E. Castellano Gauna, B. Mellado Gonzalez, P. Ivanyi, A. Floercken, C. Suarez Rodriguez, J.P. Maroto Rey, V. Gruenwald, I. Burkholder, A. Hartmann, J.B.A.G. Haanen
Journal: Annals of Oncology (2024)
226TiP CLEAR-Me: Interception trial to detect and clear molecular residual disease in patients with high-risk melanoma
Authors: E.F. Saldanha, P. Spiliopoulou, K. Huenike, S. Strum, Z. Kamil, A. Easson, S. Genta, C.G. Smith, B. Ambasager, A. Carter, C. Pipinikas, M.O. Butler, S. Saibil, A. Covelli, T. Pimentel Muniz, P.L. Bedard, L.L. Siu, T. Pugh, A. Spreafico
Journal: Annals of Oncology (2024)
LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer
Authors: R.E. Langley, M. Nankivell, D. Gilbert, E. Bourmpaki, S. Mangar, H.L. Rush, S.D. Rosen, A. Alhasso, R. Kockelbergh, J. Marshall, A. Griffiths, K.H.Y. Chan, W.M. Mohamed, N.L. Dallas, S.J. Brown, N. Clarke, N.D. James, M.K. Parmar
Journal: Annals of Oncology (2024)
LBA44 Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Authors: C. Robert, M. Carlino, C. McNeil, A. Ribas, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A.M. Arance, A. Daud, O. Hamid, J. Larkin, L. Yao, R. Singh, R. Lal, G. Long
Journal: Annals of Oncology (2024)
LBA76 Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
Authors: X. Sheng, P. Shen, W. Qu, Z. Wang, Y. Li, X. Ren, S. Jiang, G. Li, C. Fu, W. Qin, J. Wu, P. Chen, H. Guo, F. Zhou, Z. Ji, A. Yang, K. Chen, L. Li, A. Zhou, J. Guo
Journal: Annals of Oncology (2024)
LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
Authors: T.B. Powles, M.S. van der Heijden, M.D. Galsky, H. Al-Ahmadie, J.J. Meeks, H. Nishiyama, T.Q. Vu, L. Antonuzzo, P. Wiechno, V. Atduev, A.G. Kann, T-H. Kim, C. Suarez Rodriguez, C-H. Chang, F. Roghmann, M. Ozguroglu, J. Armstrong, S. Ho, S. Hois, J. Catto
Journal: Annals of Oncology (2024)
LBA63 A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
Authors: A.M. Gehrels, E. Pijnappel, E. van Daalen, S. Casalino, C. Zecchetto, A. Quinzii, G. Prager, J. de vos-Geelen, T. Macarulla Mercade, D. Melisi, H. Wilmink
Journal: Annals of Oncology (2024)
LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
Authors: H. Gelderblom, V.A. Bhadri, S. Stacchiotti, S. Bauer, A.J. Wagner, M. van de Sande, N.M. Bernthal, A. Lopez Pousa, A.R. Abdul Razak, A. Italiano, M. Ahmed, A. Le Cesne, C. Tait, A. Saunders, B. Harrow, M.G. Sharma, R. Ruiz-Soto, M.L. Sherman, J-Y. Blay, W.D. Tap
Journal: Annals of Oncology (2024)
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial
Authors: M.W. Lucas, A.M. Menzies, M. Lopez-Yurda, R.A. Scolyer, B. van de Wiel, R.P.M. Saw, W. Van Houdt, N. Maher, A. Torres Acosta, M. Boers-Sonderen, G. Hospers, M.S. Carlino, J.W. de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, S.K. Sandhu, A.A.M. Van der Veldt, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2024)
LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib
Authors: A. Le Cesne, C. Cropet, M. Brahmi, R. Bahleda, E. Bompas, T. Valentin, A. Hervieu, O. Bouche, A. Dufresne, M. Toulmonde, K. Bourcier, F. Duffaud, M. Pracht, F. Bertucci, L. Lebellec, A. Italiano, C. Henon, J. Gautier, D. Perol, J-Y. Blay
Journal: Annals of Oncology (2024)
LBA72 Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: N. Mehra, S. Van Wilpe, H. Westdorp, I. Kloots, P. Slootbeek, M. den Brok, M. Franken, M. Coskuntürk, H. Bloemendal, J. Nagarajah, J. van Ipenburg, L. Kroeze, M. Ligtenberg, J.A. Schalken, W.R. Gerritsen
Journal: Annals of Oncology (2024)
LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial
Authors: C. Ciccarese, S. Porcari, S. Buti, G. Fornarini, F. Primi, G.C. Giudice, A. Damassi, J.R. Giron Berrios, L. Stumbo, D. Arduini, A. Severino, D. Rondinella, L. Masucci, M. Sanguinetti, A. Gasbarrini, G. Cammarota, N. Segata, G. Tortora, G. Ianiro, R. Iacovelli
Journal: Annals of Oncology (2024)
Cancer in multi-lineage mosaic RASopathies due to pathogenic variants in HRAS or KRAS: a systematic review and meta-analysis
Authors: Jonas Windrich, Gina M. Ney, Philip S. Rosenberg, Jung Kim, Martin Zenker, Douglas R. Stewart, Christian P. Kratz
Journal: Clinical Cancer Research (2024)

Abstract Purpose: To determine the cancer risk and spectrum in patients with multi-lineage mosaic RASopathies with pathogenic variants (PV) in HRAS or KRAS. Methods: We conducted a systematic literature review to identify multi-lineage mosaic RASopathy cases with a PV in HRAS or KRAS to create a retrospective cohort. We calculated cumulative incidence, cancer-free survival and hazard rates (HR) for cancer and standardized incidence rates (SIR). Results: This study identified 69 patients. Seventeen percent had cancer, including rhabdomyosarcoma located in the urogenital region (n=7), skin cancer (n=3), Wilms tumor (n=1), and bladder cancer (n=1). Cumulative cancer incidence by age 20 was 20% (95% CI, 4 to 37%). The annual cancer HR peaked at 14% within the first two years of life. The highest SIR was found for rhabdomyosarcoma (SIR = 800, 95% CI, 300 to 1648). Conclusions: This is the first investigation of cancer risk in KRAS or HRAS PV-positive mosaic RASopathies to date. The high incidence and SIR values found highlight the need for rigorous rhabdomyosarcoma surveillance in young children and skin cancer surveillance in adults with this high-risk condition.
LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial
Authors: D. Schadendorf, H. Gogas, L. Kandolf Sekulovic, F. Meier, T.K. Eigentler, M. Ziemer, P. Terheyden, A. Gesierich, R. Herbst, K.C. Kähler, D.C. Ziogas, Ž. Mijušković, M. Garzarolli, C. Garbe, A. Roesch, S. Ugurel-Becker, R. Gutzmer, J.J. Grob, L. Zimmer, E. Livingstone
Journal: Annals of Oncology (2024)
LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial
Authors: S. Lorenzen, T.O. Goetze, P.C. Thuss-Patience, J. Riera Knorrenschild, E. Goekkurt, T.N. Dechow, T.J. Ettrich, R.D. Hofheinz, K. Luley, D. Pink, U. Lindig, G. Folprecht, G. Schuch, M. Bitzer, V. Heinemann, S. Angermeier, C. Bolling, S. Junge, C. Pauligk, S-E. Al-Batran
Journal: Annals of Oncology (2024)
LBA73 Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
Authors: T.K. Choueiri, R.J. Motzer, K. Beckermann, P. Barthelemy, R. Iacovelli, S. Emambux, J. Molina Cerrillo, B. Garmezy, P.M. Coelho Barata, R.R. McKay, A. Chehrazi-Raffle, H. Hammers, D.Y.C. Heng, E. Braendle, B.A. McGregor, L. Albiges
Journal: Annals of Oncology (2024)
LBA66 UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)
Authors: A.A. Azad, M. Bressel, H. Tan, M. Voskoboynik, A. Suder, A.J. Weickhardt, A. Guminski, R.J. Francis, J. Saghebi, N. Dhiantravan, A. Joshua, L. Emmett, D. Murphy, E. Hsiao, S.T. Lee, D.A. Pattison, D. Nadebaum, I.D. Kirkwood, M.S. Hofman
Journal: Annals of Oncology (2024)
LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Authors: G. Goss, G.E. Darling, V. Westeel, K. Nakagawa, B. Massuti Sureda, F. Perrone, S-A. McLachlan, J.H. Kang, Y-L. Wu, A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, S. Sugawara, E. Nadal, A. Catino, M.R. Stockler, K. Ding, C. O'Callaghan
Journal: Annals of Oncology (2024)
LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2
Authors: S. Popat, K.L. Reckamp, R. Califano, S-H. Lee, B. Melosky, J. Wang, Y. Wang, M.R. García Campelo, E. Felip, N. Girard, R.D. Gentzler, W. Nassib William Junior, T. Takahashi, M. Nagasaka, J.M. Bauml, S. Shah, B. Diorio, P-L. Chu, B.C. Cho, A. Passaro
Journal: Annals of Oncology (2024)
LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial
Authors: S. Senan, D.R. Spigel, B.C. Cho, K. Laktionov, Y. Zenke, K.H. Lee, Q. Wang, A.F. Navarro Mendivil, E.L. Buchmeier, S. Sezgin Goksu, A. Badzio, A. Shi, D.B. Daniel, M. Zemanova, P. Iyengar, L.G. Paz-Ares, L. Szadkowski, P. Chugh, W.C.V. Lai, Y. Cheng
Journal: Annals of Oncology (2024)